Evernow Raises $28.5M in Series A Funding to Redefine Menopause Treatment | Mobile Health Times
Summary
Despite this, 75 percent of women who seek treatment don’t receive it, and for those who do, a lack of specialists, low prioritization, and insufficient patient-focused education have led to many existing recommendations falling short. Evernow’s platform is meeting this challenge by using technology to match women with tailored prescription treatments and expert clinicians for ongoing virtual support through a beautifully-designed and user-friendly interface. “We’ve spent a significant amount of time exploring the women’s health space and were stunned at how little attention has been focused on the menopause market despite its permanence and enormity,” said Vanessa Larco, Partner at NEA. “Our mission is to advance our collective knowledge and improve access to the best treatments, thereby equipping women with the tools to be in control of their health and feel their best throughout the second half of their lifespan.” With more public figures becoming advocates for women’s health and well-being, Evernow’s angel investor list includes Gwyneth Paltrow, Glennon Doyle, Abby Wambach, Carla Harris (recent Vice Chairman and Managing Director at Morgan Stanley), Gwynne Shotwell, Sheila Lirio Marcelo (NEA Venture Partner and founder of Care.com and ProofofLearn), Drew Barrymore, and Cameron Diaz. This news comes on the heels of Evernow’s newest hires and advisors which include its new Chief Medical Officer, Leah Millheiser, MD, NCMP, a Stanford professor and expert in menopause and female sexual medicine; Allie Sharma, MD, MSc, a Weill Cornell-trained psychiatrist with a deep background in both private practice and population health; and the Buck Institute’s Jennifer Garrison, PhD, a leading authority on ovarian biology and expert on reproductive lifespan.